{"entity":{"id":"zevorcabtagene-autoleucel","kind":"drug","name":"Zevorcabtagene autoleucel","aka":[],"tldr":"Zevor-cel is CARsgen's myeloma CAR-T, approved in China in 2024 for patients whose disease has come back after three or more treatments.","summary":"Approved by the NMPA in February 2024 for relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory drug, on the LUMMICAR STUDY 1 phase 1/2 trial run in China. CARsgen reported high response rates with deep remissions and mostly low-grade cytokine release syndrome; the full phase 2 report appeared in Experimental Hematology and Oncology in 2025. Commercialised in China with Huadong Medicine. CARsgen's second approval, satricabtagene autoleucel for Claudin 18.2-positive gastric cancer, followed in 2025.","status":"approved","asOf":"2026-09-10","links":[{"label":"CARsgen Therapeutics","url":"https://www.carsgen.com/en/"},{"label":"Phase 2 study of zevorcabtagene autoleucel (Exp Hematol Oncol 2025)","url":"https://doi.org/10.1186/s40164-025-00710-y"},{"label":"Zevorcabtagene autoleucel: first approval (Mol Diagn Ther 2024)","url":"https://doi.org/10.1007/s40291-024-00723-z"}],"tags":["china"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["car-t"],"targets":["bcma"],"drugs":[],"companies":["carsgen"],"institutions":[],"pathways":[],"terms":[],"trials":["lummicar-1","nct03915184"],"people":[],"bottlenecks":[],"keyPapers":["paper-chen-exp-hematol-oncol","paper-dhillon-mol-diagn-ther"],"journals":[],"dependsOn":[],"notes":[],"brand":"Saikaize","code":"zevor-cel, CT053","modality":"Cell therapy (autologous BCMA CAR-T, fully human binder)","mechanism":"Autologous T cells transduced with a fully human anti-BCMA CAR (4-1BB co-stimulation) developed by CARsgen from its Shanghai platform.","approvals":[{"region":"China","year":2024,"indication":"Relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory agent"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/zevorcabtagene-autoleucel/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"}],"company":[{"id":"carsgen","kind":"company","name":"CARsgen Therapeutics","route":"/companies/carsgen/"}],"trial":[{"id":"nct03915184","kind":"trial","name":"Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)","route":"/trials/nct03915184/"},{"id":"lummicar-1","kind":"trial","name":"LUMMICAR STUDY 1","route":"/trials/lummicar-1/"}],"paper":[{"id":"paper-chen-exp-hematol-oncol","kind":"paper","name":"Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma","route":"/key-papers/paper-chen-exp-hematol-oncol/"},{"id":"paper-dhillon-mol-diagn-ther","kind":"paper","name":"Zevorcabtagene Autoleucel: First Approval","route":"/key-papers/paper-dhillon-mol-diagn-ther/"}],"person":[{"id":"li-zonghai","kind":"person","name":"Zonghai Li","route":"/people/li-zonghai/"}],"institution":[{"id":"renji-hospital","kind":"institution","name":"Renji Hospital, Shanghai Jiao Tong University","route":"/institutions/renji-hospital/"}]}}